To further investigate the clinical utility of serum miR-92b-3p for tumour monitoring, we evaluated serum miR-92b-3p and miR-150-3p levels, as well as white blood cell (WBC) counts and hemoglobin (Hb) levels in SS patients from whom we could obtain a series of serum samples during multimodal treatment. This evidence concerns the gene GSTM1 and neoplasm.